---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-103"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-103. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 60 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-103"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-103

<a id="heading-3.1.4"></a>

## 3.1.4 ABX464-103

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.”
> “A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.1-2"></a>

#### Aim stated in the published report

> “We aimed to assess ABX464 as a treatment for patients with moderate-to-severe, active ulcerative colitis.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.1-3"></a>

#### Primary objective in the protocol: dose selection

> “The primary objective of the study is to determine an optimal ABX464 dose to be used in moderate to severe active ulcerative colitis patients who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab, JAK inhibitors and/or corticosteroids by comparing the mean change from baseline in the MMS at week 8 between each ABX464 group and placebo.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.1-4"></a>

#### Selected secondary objectives in the protocol

> “To evaluate the effect of the different dose groups of ABX464 on clinical remission at Week 8 and at Week 16 (if available) versus placebo.”
> “To evaluate the effect of the different dose groups of ABX464 on Quality of Life (QoL) measured by the IBDQ at Week 8 and Week 16 versus placebo.”
> “To assess the pharmacokinetics of the ABX464 and its main active metabolite ABX464-N-Glu after oral administration of different daily doses of ABX464 using population approach.”
> “To evaluate the safety profile of the different dose groups of ABX464 versus placebo.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.1-5"></a>

#### Rationale for the study in the protocol: phase 2a results

> “A Phase IIa study (ABX464-101) aimed at evaluating the efficacy and safety of ABX464 given at a fixed dose of 50mg once daily versus Placebo in Patients with Moderate to Severe Active Ulcerative Colitis who have failed or are Intolerant to immunomodulators, Anti-TNFα or Corticosteroids was conducted in Belgium, France, Germany, Austria, Poland, Hungary.”
> “These efficacy and safety results warrant the continuation of the clinical development of ABX464 in this indication.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2019-08-13”
> “Primary Completion (Actual) 2021-04-01”
> “Study Completion (Actual) 2021-04-16”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.2-2"></a>

#### Results posting dates

> “Results First Submitted 2024-05-17”
> “Results First Posted 2025-11-28”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.2-3"></a>

#### Registered locations

> “This study has 130 locations”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.2-4"></a>

#### Centres, countries, and enrollment period in the published report

> “In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.”
> “Between Aug 13, 2019, and April 16, 2021, 254 patients were randomly allocated to ABX464 100 mg (n=64), ABX464 50 mg (n=63), ABX464 25 mg (n=63), or placebo (n=64).”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.2-5"></a>

#### Planned sites in the protocol

> “Up to 244 patients will be randomized in this study. These patients will be enrolled in approximately 110 to 150 sites located in Europe, Canada and in the USA.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.2-6"></a>

#### Trial registration printed in the published abstract

> “This study is registered with ClinicalTrials.gov, NCT04023396.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Randomised, double-blind, placebo-controlled, four-group design

> “In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.”
> “Enrolled patients were randomly assigned (1:1:1:1) via an interactive voice and web response system to receive once daily oral ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, or matched placebo.”
> “Randomisation was stratified according to study site (US vs non-US) and to whether the patient had previous exposure to second-line treatment with biologics or JAK inhibitors.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.3-2"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double blind, placebo controlled, parallel groups” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Enrollment (actual) | “355” |

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.3-3"></a>

#### Treatment groups and duration in the ClinicalTrials.gov record

> “Eligible patients will be randomized into 4 parallel intervention/treatment groups: 100mg q.d of ABX464, 50mg q.d of ABX464, 25mg q.d of ABX464, or matching placebo and will be treated for 16 weeks.”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.3-4"></a>

#### Limits on previous advanced therapy exposure, central endoscopy reading, and e-diaries

> “The proportion of patients with previous exposure to biologics or JAK inhibitors will be limited to 60%, including a maximal proportion of patients with previous treatment with vedolizumab of 20%. The maximal proportion of patients with previous exposure with JAK inhibitors will be limited to 10%.”
> “Patients will be treated for 16 Weeks in this induction study. All endoscopies (videos) will be centrally reviewed. E-Diaries will be used to collect frequency of stools, rectal bleedings, number of capsules taken and the intake time.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.3-5"></a>

#### Endoscopy schedule and exit for disease progression

> “Flexible sigmoidoscopy with rectal and sigmoidal (if the sigmoidal is inflamed) biopsies will be performed at screening, at Day 57 +/- 4 days (week 8) and at Day 113 +/- 4 days (week16). The Day 113 measurement will only be performed if patient does not experience endoscopic improvement at Day 57 (i.e.: endoscopy sub-score of 2 or 3).”
> “From Week 8 onwards, in the event of clinical progression of the disease defined as at least a 2-point increase from the screening in partial Modified Mayo Score (pMMS) with a Modified Mayo Score ≥ 4 confirmed by an endoscopy sub score of 2 points or higher, the patient will exit definitively the study.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.3-6"></a>

#### Duration of participation and roll-over to the open-label extension

> “Patients will be treated for 16 Weeks. At Week 16, regardless of their clinical/symptomatic response and the actual treatment/dose received, patients willing to continue the study treatment and eligible for enrollment will roll over in an Open Label Extension study (ABX464-104).”
> “Thus, the total duration of the study participation is 21 Weeks.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.3-7"></a>

#### Dose limiting toxicity rule and Data Safety Monitoring Board

> “A dose limiting toxicity (DLT) is defined as a grade 3 or higher adverse event as defined by the Common Terminology Criteria for Adverse Events (CTC-AE V5.0) considered by a safety review board as probably or definitely related to study treatment.”
> “The DSMB will meet every 2 months.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Key eligibility criteria in the published report

> “Eligible patients were aged 18-75 years, with a diagnosis of moderate-to-severe, active ulcerative colitis and a modified Mayo Score (MMS) of 5 points or higher, and a documented non-response or intolerance to previous treatment.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.4-2"></a>

#### Inclusion criteria in the ClinicalTrials.gov record: disease activity and previous treatment

> “Men or women age 18 - 75 years;”
> “Moderate to severe active UC defined by Modified Mayo Score (MMS) of 5 to 9 inclusive (on a scale of 0-9). Moderate to severe active UC should be confirmed at screening visit with a centrally read endoscopy sub-score of at least 2 (on a scale of 0-3);”
> “Patients having either a documented inadequate response, no response, a loss of response, or an intolerance (defined as the occurrence of at least one Adverse Reaction leading to treatment discontinuation) to either immunosuppressant treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor [TNF] inhibitors, vedolizumab, JAK inhibitors and/or corticosteroid treatment.”
> “18 Years to 75 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.4-3"></a>

#### Inclusion criteria in the ClinicalTrials.gov record: background therapy and washout

> “Patients receiving oral corticosteroids must have been on a stable dose of prednisone or prednisone equivalent (≤20 mg/day) or on beclomethasone diproprionate (≤5mg/day) or on budesonide MMX (≤9 mg/day) for at least 2 Weeks prior to the screening visit;”
> “Patients who have received tumor necrosis factor [TNF] inhibitors, vedolizumab or other biologics must have discontinued therapy at least 8 Weeks prior to the screening visit due to lack or insufficient efficacy or intolerance;”
> “Patients previously treated with cyclosporine, tacrolimus or JAK inhibitors must have discontinued therapy at least 4 Weeks prior to the screening visit due to lack or insufficient efficacy or intolerance;”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.4-4"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Patients with Crohn's Disease (CD) or presence or history of fistula, indeterminate colitis (IC), infectious/ischemic colitis or microscopic colitis (lymphocytic and collagenous colitis);”
> “History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma; history or imminent colectomy, colonic malignancy;”
> “History of more than one episode of herpes zoster or a history (single episode) of disseminated zoster;”
> “Patients previously treated with ABX464;”
> “Acute, chronic or history of immunodeficiency or autoimmune disease;”
> “Pregnant or breast-feeding women;”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Arms and capsule regimens in the ClinicalTrials.gov record

> “ABX464 100 mg (two capsules of ABX464 50 mg) once daily for 16 weeks”
> “ABX464 50 mg (one capsule of ABX464 50 mg + one capsule of placebo) once daily for 16 weeks”
> “ABX464 25 mg (one capsule of ABX464 25 mg + one capsule of placebo) once daily for 16 weeks”
> “Two capsules of placebo once daily for 16 weeks”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.5-2"></a>

#### Formulation and administration in the protocol

> “For the proposed clinical trial, the IMP consists of size 01 capsules containing either 25mg or 50mg of ABX464 drug substance”
> “All patients regardless of the treatment group will receive 2 capsules every day.”
> “Patients will be orally dosed in a fed condition (regular meal) in the morning with a glass of water.”
> “No intra-patient dose escalation/dose adjustment are allowed.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.5-3"></a>

#### Allowed concomitant medications in the protocol

> “Corticosteroids at stable dose of prednisone or prednisone equivalent ≤20 mg/day; beclomethasone diproprionate (≤5mg/day) or budesonide MMX (≤9 mg/day);”
> “Oral 5-aminosalicylic acid at stable dose;”
> “Immunosuppressants in the form of azathioprine, 6-mercaptopurine, or methotrexate at stable dose;”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.5-4"></a>

#### Prohibited medications in the protocol, including CYP1A2 substrates

> “JAK inhibitors with a wash-out period of at least 4 Weeks prior to the screening visit;”
> “Vaccination with live components during the study and up to 8 Weeks after the last dosing;”
> “The following CYP1A2 substrates with a narrow therapeutic margin are prohibited during the whole course of the study (Clozapine, theophylline, ropinirol, warfarin and methadone).”
> “Drugs that inhibit UGTIA9 activity and inhibitors of OATP1B1/1B3 transporters (cf. Appendix #1).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Change in Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint in the published report

> “The primary endpoint was the change from baseline in MMS at week 8.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.6.1-2"></a>

##### Registered primary outcome measure and the modified Mayo score

> “Reduction From Baseline in Modified Mayo Score (MMS) at Week 8”
> “MMS is a composite score of UC disease activity based on the following 3 subscores:”
> “The overall MMS ranges from 0 to 9 where higher scores represent more severe disease.”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.6.1-3"></a>

##### Modified Mayo score compared with the total Mayo score in the protocol

> “The Stool and Rectal Bleeding frequency assessment will be based on the Mayo scoring system which is the most commonly used index in clinical trials.”
> “Total Mayo score consists of 4 items: stool frequency, rectal bleeding, flexible sigmoidoscopic examination, and a physician global assessment (Appendix #3). Modified Mayo Score (MMS) consists of 3 items (stool frequency, rectal bleeding, flexible sigmoidoscopic examination).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.6.1-4"></a>

##### Secondary endpoint definitions in the protocol: clinical remission, clinical response, endoscopic improvement, and mucosal healing

> “Clinical remission, based on the Mayo Scoring system, is defined as stool frequency subscore = 0 or 1 and rectal bleeding subscore = 0 and endoscopy subscore = 0 or 1 (modified to exclude friability).”
> “Clinical Response is defined as a reduction in Mayo Score of at least 2 points and greater than or equal to 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of greater than or equal to 1 point or absolute rectal bleeding sub-score of less than or equal to 1 point.”
> “Endoscopic improvement is defined as a Mayo endoscopic sub score of ≤1 (excluding friability) and endoscopic remission defined as sub score of 0.”
> “Mucosal healing is defined as both endoscopic remission and histological remission (Geboes score < 2.0).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.6.1-5"></a>

##### Central reading of endoscopy in the registered secondary outcomes

> “Endoscopies were assessed by a blinded central reader and scored according to the following scale:”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Sample size assumptions in the protocol

> “mean reduction in MMS (ABX464): 2.5”
> “mean reduction in MMS (placebo): 1.0”
> “pooled standard deviation of reduction in MMS: 2.1”
> “If the above assumptions hold true, then a total sample size of 232 subjects will be required to be randomized (58 subjects randomized to each study treatment arm).”
> “Due to the SARS Cov-2 pandemic the drop-out rate of the study is expected to be somewhat higher than originally estimated. Therefore, an additional 12 subjects are planned to be recruited in the study leading to an overall sample size of 244 patients (61 subjects randomized to each study treatment arm).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

##### Participants consented, randomized, treated, and analyzed in the posted results

> “A total of 355 patients consented to participate, 254 patients were randomized. A total of 253 patients were treated, 222 patients completed study treatment.”
> “A total of 252 patients were included in the FAS (64: ABX464 100mg q.d, 63: ABX464 50mg q.d, 61: ABX464 25mg q.d and 64: placebo).”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.7.1-3"></a>

##### Exclusions from the full analysis set in the published report

> “Two patients, both in the ABX464 25 mg group, were excluded from the FAS.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.7.1-4"></a>

##### Participants analyzed for the primary outcome in the posted results

| Group | Participants analyzed, change in MMS at week 8 |
| --- | --- |
| ABX464 100 mg | “58” |
| ABX464 50 mg | “54” |
| ABX464 25 mg | “59” |
| Matching placebo | “60” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Full analysis set and safety population in the published report

> “The primary efficacy analysis was done in the full analysis set (FAS), defined as all randomly assigned patients who received at least one dose of study treatment and had baseline data for at least one efficacy variable, and was analysed according to the principles of intention-to-treat.”
> “Safety analyses included patients who had been randomly assigned and who received at least one dose of study treatment.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.7.2-2"></a>

##### Analysis sets in the statistical analysis plan

> “The Safety Analysis Set (SAF) will include all randomized patients who have received at least one dose of the study treatment.”
> “The Full Analysis Set (FAS) will include all patients included in the study who have received at least one dose of the study treatment, and who have baseline data for at least one efficacy variable.”
> “The Per Protocol Analysis Set (PPAS) will include all patients in the FAS who do not have major PDs that would affect the evaluation of the primary efficacy endpoint.”

Source: [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf)

<a id="topic-3.1.4.7.2-3"></a>

##### Handling of missing week 8 data

> “A subject’s missing efficacy data viz. MMS (or any components of MMS missing) at Week 8, will be imputed and the subject will be considered as a non-responder for clinical remission and response.”

Source: [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf)

<a id="topic-3.1.4.7.2-4"></a>

##### Primary analysis model and fixed testing sequence in the protocol

> “This change will be compared between subjects who received ABX464 and placebo for each ABX464 treatment arm separately using an ANCOVA model adjusting for randomized study treatment arm, previous biological or JAK inhibitors treatment use (i.e. randomization strata), and baseline MMS.”
> “The dose testing will commence with comparing the ABX464 50mg dose with placebo. If this is significant at a 5% two-sided level (i.e. p<0.05) a comparison against placebo will be carried out at the ABX464 100mg dose. Again, if significance at a 5% level for this test is observed the procedure will be repeated at the ABX464 25mg dose.”
> “Analysis of efficacy data will be carried out in the Full Analysis Set in which subjects who prematurely discontinue the study due to adverse reaction(s) will be considered treatment failures.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Participant flow in the posted results

| Measure | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| Started | “64” | “63” | “63” | “64” |
| Treated | “64” | “63” | “62” | “64” |
| Full analysis set | “64” | “63” | “61” | “64” |
| Completed | “54” | “53” | “58” | “57” |
| Not completed | “10” | “10” | “5” | “7” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.1-2"></a>

##### Discontinuations and exclusions in the posted results

> “32 patients discontinued and 1 patient was randomized but did not receive study drug. One further patient was excluded from the Full Analysis Set (FAS) due to noncompliance with inclusion/exclusion criteria.”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Baseline characteristics in the posted results

| Characteristic | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo | Total |
| --- | --- | --- | --- | --- | --- |
| Participants | “64” | “63” | “61” | “64” | “252” |
| Age, years, mean (SD) | “42.2(12.34)” | “40.2(13.94)” | “41.5(14.16)” | “41.1(14.43)” | “41.2(13.67)” |
| Female | “23” | “36” | “21” | “24” | “104” |
| Male | “41” | “27” | “40” | “40” | “148” |
| Baseline MMS 5 to 6 | “17” | “16” | “17” | “21” | “71” |
| Baseline MMS 7 to 9 | “47” | “47” | “44” | “42” | “180” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.2-2"></a>

##### Race and ethnicity not collected

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.2-3"></a>

##### Disease severity and refractoriness of the induction population

> “Of the 252 patients treated in the induction trial, baseline disease activity was severe (MMS of 7–9) in 71.4% of patients, and more than 45% of patients were refractory to 2 or more advanced targeted therapies at baseline.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.4.8.2-4"></a>

##### Participants enrolled by country in the posted results, selected countries

| Country | Total participants |
| --- | --- |
| Poland | “70” |
| Ukraine | “32” |
| France | “30” |
| Hungary | “22” |
| Italy | “20” |
| United States | “2” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Induction results reported in the maintenance study publication

> “More than 45% had failed at least 2 prior advanced targeted therapies (biologics or JAK inhibitors). Obefazimod (25, 50, or 100 mg) significantly reduced the modified Mayo score (MMS) at week 8, meeting the primary endpoint. Improvements were seen in both naïve and bio/JAK refractory patients in key secondary outcomes, including clinical remission, response, endoscopic, and histologic–endoscopic mucosal improvement.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.4.8.3-2"></a>

##### Primary endpoint: change from baseline in modified Mayo score at week 8

> “In the FAS at week 8, the least squares mean (LSM) change from baseline in MMS was -2·9 (95% CI -3·4 to -2·5) for the ABX464 100 mg group, -3·2 (-3·7 to -2·7) for the ABX464 50 mg group, -3·1 (-3·6 to -2·6) for the ABX464 25 mg group, and -1·9 (-2·4 to -1·5) for placebo group; the magnitude of the difference in MMS from baseline was significantly greater in all three ABX464 groups compared with placebo (p=0·0039 for ABX464 100 mg vs placebo, p=0·0003 for ABX464 50 mg vs placebo, and p=0·0010 for ABX464 25 mg vs placebo).”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.8.3-3"></a>

##### Investigators' interpretation

> “All doses of ABX464 significantly improved moderate-to-severe, active ulcerative colitis compared with placebo, as measured by changes in MMS from baseline to week 8.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.8.3-4"></a>

##### Primary outcome in the posted results: least squares mean change in MMS at week 8

| Group | Least squares mean | 95% confidence interval |
| --- | --- | --- |
| ABX464 100 mg | “-2.9” | “(-3.4 to -2.5)” |
| ABX464 50 mg | “-3.2” | “(-3.7 to -2.7)” |
| ABX464 25 mg | “-3.1” | “(-3.6 to -2.6)” |
| Matching placebo | “-1.9” | “(-2.4 to -1.5)” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.3-5"></a>

##### Secondary outcomes at week 8 in the posted results: number of participants

| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| Clinical remission per MMS (64, 63, 61, 64) | “16” | “11” | “16” | “8” |
| Clinical response (64, 63, 61, 64) | “32” | “37” | “38” | “22” |
| Endoscopic improvement (54, 53, 58, 59) | “24” | “21” | “20” | “8” |
| Endoscopic remission (54, 53, 58, 59) | “2” | “5” | “4” | “5” |
| Mucosal healing (64, 63, 61, 64) | “0” | “1” | “0” | “2” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.3-6"></a>

##### Secondary outcomes at week 16 in the posted results: number of participants

| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| Clinical remission per MMS (31, 30, 37, 46) | “7” | “6” | “9” | “6” |
| Clinical response (31, 30, 37, 46) | “19” | “20” | “25” | “20” |
| Endoscopic improvement (32, 31, 38, 46) | “11” | “12” | “11” | “9” |
| Endoscopic remission (32, 31, 38, 46) | “1” | “1” | “2” | “3” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.3-7"></a>

##### Analysis population for the week 16 outcomes

> “Number of patients in the category with data available for baseline and the respective visit.”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

##### IBDQ planned as a secondary endpoint in the protocol

> “The scores and changes from baseline in IBDQ at Week 8 and Week 16 per intervention treatment group.”
> “The Inflammatory Bowel Disease Questionnaire (IBDQ) is a widely used questionnaire for HRQoL assessment in patients with inflammatory bowel diseases (IBDs).”
> “IBDQ will be filled in by the patients at Day 1, Day 57 and Day 113 prior to any study procedures.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.8.4-2"></a>

##### Stool frequency and rectal bleeding recorded in an electronic diary

> “Participants recorded stool frequency using an electronic subject diary on a daily basis.”
> “Participants recorded rectal bleeding in an electronic subject diary on a daily basis.”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Headache and serious adverse events in the published report

> “The most frequently reported adverse event was headache, which was reported for 27 (42%) of 64 patients in the ABX464 100 mg group, 19 (30%) of 63 in the 50 mg group, 13 (21%) of 62 in the 25 mg group, and five (8%) of 64 in the placebo group.”
> “Severe (grade 3) headache was reported for three (5%) patients in the ABX464 group 100 mg group, two (3%) in the ABX464 50 mg group, one (2%) in the ABX464 25 mg group, and none in the placebo group.”
> “The only serious adverse event reported for two or more patients in any group was ulcerative colitis (one in each of the ABX464 100 mg and 50 mg groups, and three [5%] in the placebo group).”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.8.5-2"></a>

##### Adverse events in the posted results: participants affected / at risk (%)

| Event | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| All-cause mortality | “0/64 (0.00%)” | “0/63 (0.00%)” | “0/62 (0.00%)” | “0/64 (0.00%)” |
| Serious adverse events, total | “4/64 (6.25%)” | “4/63 (6.35%)” | “1/62 (1.61%)” | “4/64 (6.25%)” |
| Other adverse events, total | “45/64 (70.31%)” | “38/63 (60.32%)” | “33/62 (53.23%)” | “30/64 (46.88%)” |
| Headache | “27/64 (42.19%)” | “19/63 (30.16%)” | “13/62 (20.97%)” | “5/64 (7.81%)” |
| Nausea | “9/64 (14.06%)” | “4/63 (6.35%)” | “5/62 (8.06%)” | “4/64 (6.25%)” |
| Vomiting | “5/64 (7.81%)” | “2/63 (3.17%)” | “1/62 (1.61%)” | “1/64 (1.56%)” |
| Abdominal pain upper | “4/64 (6.25%)” | “3/63 (4.76%)” | “3/62 (4.84%)” | “0/64 (0.00%)” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.5-3"></a>

##### Adverse event collection period in the posted results

> “TEAEs and SAEs were collected from enrollment to end of study: up to 24 weeks in total, including 4 weeks screening (prior the first dose of study drug), 16 weeks of treatment, and 4 weeks safety follow-up (28 days after last dose of study drug).”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

ABX464-103 was a phase 2b, randomized, double-blind, placebo-controlled dose-ranging induction trial with 4 parallel groups; 254 participants were randomized and 252 were included in the full analysis set. The primary endpoint was the change from baseline in modified Mayo score at week 8, and the protocol also defined clinical remission, clinical response, and endoscopic improvement as outcomes. The posted results report the primary outcome for 58, 54, 59, and 60 participants in the 100 mg, 50 mg, 25 mg, and placebo groups, against full analysis set sizes of 64, 63, 61, and 64. The protocol scheduled week 16 endoscopy only for participants without endoscopic improvement at week 8, and the week 16 outcomes were analyzed in participants “with data available for baseline and the respective visit”. The protocol limited participants with previous exposure to biologics or JAK inhibitors to 60%, those with previous vedolizumab to 20%, and those with previous JAK inhibitors to 10%. Of 252 participants, 2 were enrolled in the United States, and race and ethnicity were not collected. The protocol planned IBDQ assessment at Week 8 and Week 16, and no IBDQ results were located in the PubMed abstract or the posted results. Headache was reported in 27 of 64, 19 of 63, 13 of 62, and 5 of 64 participants in the 100 mg, 50 mg, 25 mg, and placebo groups. The PubMed abstract gives NCT04023396, the record of the open-label maintenance study, as the trial registration.

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/); [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results); [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf); [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf); [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003); [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.4.9-2"></a>

#### Limitations and caveats field in the posted results

> “Limitations and Caveats [Not Specified]”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.9-3"></a>

#### Publication agreement disclosed in the posted results

> “There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
